Table 1.

Demographic and hormone characteristics of 88 postmenopausal women stratified by history of hormone therapy use

Baseline characteristicsNever users (n = 45)Former users

All former users (n = 43)
Used <5 y ago (n = 20)
Used ≥5 y ago (n = 19)
n (%)n (%)n (%)n (%)
Ethnicity
    Non-Hispanic White36 (80.0)41 (95.3)18 (90.0)19 (100.0)
    Other9 (20.0)2 (4.7)2 (10.0)0 (0)
Mean (SD)Mean (SD)Mean (SD)Mean (SD)
Age (y)60.5 (7.4)60.6 (6.3)58.1 (5.1)62.5 (6.6)
Percent mammographic density (%)6.7 (6.1)5.8 (4.6)6.6 (4.6)4.7 (4.2)
Dense breast area (1,000 pixels)27.4 (24.1)22.9 (14.9)24.8 (13.2)19.5 (15.3)
Total breast area (1,000 pixels)427.9 (100.0)427.3 (76.5)415.4 (82.5)448.6 (71.2)
Percent fat mass (dual-energy X-ray absorptiometry; %)43.4 (2.7)43.7 (3.1)43.7 (3.5)43.7 (3.1)
Estrone (pg/mL)48.0 (12.4)48.4 (19.9)50.0 (20.8)48.5 (205)
Estradiol (pg/mL)18.9 (5.9)18.7 (7.9)18.6 (8.7)19.5 (7.9)
Free estradiol (pg/mL)0.51 (0.18)0.51 (0.25)0.52 (0.28)0.53 (0.23)
Testosterone (pg/mL)237.4 (89.3)230.7 (106.3)249.8 (132.3)226.7 (77.4)
Free testosterone (pg/mL)5.1 (2.0)5.0 (2.4)5.6 (3.2)4.8 (1.2)
Androstenedione (ng/mL)613.2 (225.1)583.4 (251.6)617.3 (310.7)582.9 (192.0)
DHEA (ng/mL)2.7 (1.3)2.7 (1.6)3.0 (2.0)2.5 (1.2)
DHEA sulfate (μg/mL)67.1 (41.7)80.9 (67.1)96.3 (89.7)68.3 (33.9)
SHBG (nmol/L)42.3 (29.3)38.2 (19.7)35.8 (14.1)39.4 (21.3)
Follicle-stimulating hormone (mIU/L)68.0 (24.3)63.8 (19.9)67.7 (23.1)59.5 (17.6)
IGF-I (ng/mL)106.6 (31.5)111.7 (28.6)111.5 (32.1)110.9 (27.0)
IGFBP-3 (μg/mL)3.9 (1.0)4.1 (1.0)4.2 (0.9)3.8 (0.9)
IGF-I/IGFBP-3 ratio28.8 (12.1)28.5 (8.7)26.9 (5.3)30.3 (10.8)
Total cholesterol (mg/dL)*228.0 (38.2)239.6 (49.8)246.5 (65.1)237.6 (28.6)
LDL (mg/dL)147.5 (35.6)160.2 (52.3)170.4 (69.1)155.3 (26.8)
HDL (mg/dL)55.2 (12.9)52.5 (14.1)49.9 (13.8)54.6 (14.6)
LDL/HDL ratio2.8 (1.0)3.4 (2.1)3.6 (2.9)3.1 (1.0)
Total cholesterol/HDL ratio4.4 (1.3)5.0 (2.3)5.5 (3.1)4.6 (1.2)
  • * n = 43 never users and 40 former users.

  • n = 41 never users and 40 former users.